Biotech Values

[drbio45]

in what respect was it short. the people in the chonic phase had long responses. People with accelerated phase and blast phase had shorter responses. One of the people in blast phase which is an end of life scenario lived over a year.

four out of forty patients had no trace of cancer. so it would make sense that the earlier Omacetaxine is give the more chance there would be to rid the patient of the disease but it is only given in people that have failed the other drugs.

the big problem with chemgenex is that there is no coverage in the US so there is no one to enlighten US investors to the drugs positives.

the analyst in Australia that covers it thinks that ANDA's get approved in six months.